PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
10.44%
Operating income growth under 50% of CRVO's 90.98%. Michael Burry would be concerned about deeper cost or sales issues.
10.28%
Net income growth under 50% of CRVO's 50.68%. Michael Burry would suspect the firm is falling well behind a key competitor.
12.12%
EPS growth of 12.12% while CRVO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
10.49%
Diluted EPS growth of 10.49% while CRVO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
2.21%
Share change of 2.21% while CRVO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Negative OCF growth while CRVO is at 12.22%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-28.93%
Negative FCF growth while CRVO is at 12.22%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4997.65%
Negative 10Y OCF/share CAGR while CRVO stands at 97.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
52.56%
5Y OCF/share CAGR at 50-75% of CRVO's 89.49%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
56.42%
3Y OCF/share CAGR at 50-75% of CRVO's 88.67%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-10058.37%
Negative 10Y net income/share CAGR while CRVO is at 99.24%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.69%
5Y net income/share CAGR similar to CRVO's 96.59%. Walter Schloss might see both on parallel mid-term trajectories.
51.37%
3Y net income/share CAGR 50-75% of CRVO's 91.29%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
741.48%
Positive growth while CRVO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
108.54%
Positive 5Y equity/share CAGR while CRVO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-89.94%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-40.69%
We have a declining book value while CRVO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
499.58%
Debt growth of 499.58% while CRVO is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
-14.73%
Our R&D shrinks while CRVO invests at 24.49%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.54%
We expand SG&A while CRVO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.